Proton Pump Inhibitors and Lymphocytic Esophagitis : A Novel Association?

Salima Haque, Robert M. Genta, Miraca Life Sciences Research Institute, Irving, TX

Lymphocytic esophagitis was first described by Rubio et al. as an entity in 2006; however, in 2008 Purdy et al. reviewed 42 cases of lymphocytic esophagitis and dismissed it as a non-specific response of uncertain relevance. We recently reviewed the histopathology and clinical correlations of 42 patients with dense lymphocytic infiltrates in the esophageal mucosa and concluded that lymphocytic esophagitis is a specific type of inflammatory disorder of the esophagus.

To read the rest of this article, please contact Miraca Life Sciences

Choose Miraca for Your Patients


Learn more about Miraca's Anatomic Pathology services

Learn More »
TRADESHOWS >> FIND posters and presentations from past shows, and see where Miraca Life Sciences will be next.

The structured data from EMA and the Miraca interface simplifies this process, which has saved us thousands of dollars in penalties, and allowed us to qualify for the full incentives every year the program has been in effect.
— Josephine Chu McAllister, MD,
Dermatologist/Founder, Dermatology Associates of Ithaca, Ithaca, N.Y.


READ MORE
Learn about Miraca's unmatched quality. We provide our clients with access to the highest quality AP services.
Get news from Miraca. Join our email list.